Trial Profile
Evaluation of prolactinoma-associated atherosclerosis after discontinuation of cabergoline therapy in patients with prolactinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 18 Dec 2015
Price :
$35
*
At a glance
- Drugs Cabergoline (Primary)
- Indications Prolactinoma
- Focus Adverse reactions
- 18 Dec 2015 New trial record